Contents: News Stories, 2006 Nanoprobes Demonstrates the Use of Gold Nanoparticles as Superior X-Ray Contrast Agents (July 20, 2006) First 3D Distribution of 45S rDNA in Metaphase Chromosomes by in situ hybridization with FluoroNanogold (July 20, 2006) Nanoprobes, Incorporated Completes Major Expansion (March 15, 2006) Browse the company news archive...   12/21/07: 1-Hr His-Tag Detection on Westerns 8/21/07: Review Paper: Enzmet for In Situ Hybridization 4/17/07: Announcing AuroVist: Xray Contrast for MicroCT 1/10/07: Phase 2 SBIR Grant for MicroCT Imaging   11/10/06: Gold X-Ray Contrast Agents 7/20/06: First 3D Distribution of 45S rDNA 3/15/06: Major Expansion Completed   9/5/03: New Product: Ni-NTA-Nanogold® 3/25/03: New Product: Alexa FluoroNanogold   9/9/02: NIH SBIR: MRI Contrast Agents 9/4/02: NIH STTR: Her-2/neu Assay 7/8/02: NIH SBIR: Molecular Beacons II   10/9/01: NIH SBIR: Enzyme Metallography 10/9/01: Reagents from Molecular Probes   9/5/00: NIH SBIR: Molecular Beacons 6/16/00: NIH STTR: Her-2/neu Amplification 4/19/00: Phase II of "Fast-Track" NIH SBIR grant 3/9/00: Larger Nanoprobes Facility 3/9/00: New NIH NCI SBIR Grant   11/15/99: New NIH NIDDK SBIR Grant 9/23/99: New NIH "Fast-Track" SBIR Grant 9/15/99: Gold Enhancement 9/15/99: Cy3-FluoroNanogold 1/29/99: NSF SBIR: Interconnect Fabrication   9/11/98: Phase I SBIR Grant 4/3/98: Phase II of "Fast-Track" SBIR Grant   9/8/97: "Fast-Track" SBIR Grant 9/5/97: New FluoroNanogold Papers 4/27/97: SBIR - Membrane Protein Labels.   10/7/96: SBIR - Ni-NTA-Gold probes 10/3/96: NIH Phase II SBIR 8/20/96: Ultrasensitive In Situ Hybridization 8/20/96: Gold Lipids 5/25/96: Nanogold-Peptide Probes 2/22/96: NSF Phase I SBIR to Nanoprobes   10/17/95: Phase II SBIR to Nanoprobes   10/94: 3, 5, 10, 15 and 30nm Colloidal Gold 9/94: FluoroNanogold 6/92: Nanogold® Gold Labeling Reagents   News Index

Nanoprobes Demonstrates the Use of Gold Nanoparticles as Superior X-Ray Contrast Agents

In studies in mice, a 5 mm tumor growing in one thigh was clearly evident from its increased vascularity and resultant higher gold content. The gold particles thus enable direct imaging, detection, and measurement of angiogenic and hypervascularized regions. The 1.9 nm gold nanoparticles were found to clear through the kidneys: a closer examination of the kidneys revealed a remarkably detailed anatomical and functional display, with blood vessels less than 100 m in diameter delineated, thus enabling in vivo vascular casting. Toxicity was also low: mice intravenously injected with the gold nanoparticles at 2.7 g Au kg^-1 survived over one year without signs of illness. In a 30-day study using 60 mice, intravenous injection of the gold nanoparticles (at 700 mg Au kg-1) produced no evidence of toxicity in any animals. Even when concentrated, gold nanoparticle solutions were similar to water in viscosity, in sharp contrast to the high viscosity of iodine contrast media. The gold nanoparticles may be completely dried and later resuspend easily in water or aqueous buffers, such as phosphate buffered saline, pH 7.4. Solubility was found to be at least 1.5 g Au ml^-1.

Nanoprobes is developing this reagent for commercial introduction, and products based on this technology are near release. Nanoprobes, Inc., founded in 1990, researches and develops novel microscopic and biomedical staining and imaging technology using metal nanoparticles. The company is a leader in immunogold technology. Other products include the 1.4 nm Nanogold® immunoprobes and labeling reagents, FluoroNanogold combined fluorescent and gold probes, and silver enhancers and gold-based autometallographic enhancers for ultrasensitive detection and visualization of biological targets. New product announcements and information about current products are available on the companys web site (www.nanoprobes.com). Nanoprobes recently announced a major expansion to its Yaphank, NY facility.

Hainfeld J. F.; Slatkin D. N.; Focella T. M., and Smilowitz H. M.: Gold nanoparticles: a new X-ray contrast agent. Br. J. Radiol., 79, 248-253 (2006).

For more information, contact:

contents

First 3D Distribution of 45S rDNA in Metaphase Chromosomes by in situ hybridization with FluoroNanogold

Our recently introduced ALEXA FLUOR®* FLUORONANOGOLD combines the brightness and low bleaching of Alexa Fluor dyes with the high resolution and specificity of the 1.4 nm NANOGOLD®, all in one stable, covalently linked probe, enabling visualization of targets by fluorescence microscopy, then more detailed ultrastructural study by electron microscopy with direct correlation of results. Covalent attachment of both the ALEXA dye and NANOGOLD to the Fab antibody fragment ensure stability and shelf-life of this unique new dual probe.

Nanoprobes, Inc., founded in 1990, researches and develops novel microscopic and biomedical staining and imaging technology using metal nanoparticle immunoprobes. The company is a leader in immunogold technology. In addition to FLUORONANOGOLD, products include the 1.4 nm Nanogold® immunoprobes and labeling reagents, and silver enhancers and gold-based autometallographic enhancers for ultrasensitive visualization of biological targets. The Company recently announced a major expansion to its Yaphank, NY facility.

* Alexa Fluor is a trademark of Molecular Probes / Invitrogen.

For more information, contact:

contents

Nanoprobes, Incorporated Completes Major Expansion

Nanoprobes, Inc., founded in 1990, researches and develops novel biomedical and microscopic staining and imaging technology using metal nanoparticles and autometallography. The company is a leader in immunogold technology, with products which include the 1.4 nm Nanogold® immunoprobes and labeling reagents, FluoroNanogold combined fluorescent and gold probes, and autometallographic enhancers for ultrasensitive visualization of biological targets. The Company recently executed a licensing agreement with Ventana Medical Systems, Incorporated (VMSI) for the use of its Enzyme Metallography (EnzMet) technology as an ultrasensitive staining method for in situ hybridization and immunohistochemistry.

For more information, contact:

contents